HIMS and SRPT ALERTS: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm

Core Viewpoint - Class actions have been initiated on behalf of stockholders of Hims & Hers Health, Inc. and Sarepta Therapeutics, Inc. due to alleged misleading statements and undisclosed material facts regarding their business operations and prospects [1][4]. Hims & Hers Health, Inc. (NYSE: HIMS) - Class period is from April 29, 2025, to June 23, 2025, with a lead plaintiff deadline of August 25, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion of illegitimate versions of Wegovy, risking patient safety and jeopardizing collaboration with Novo Nordisk [2][3]. - Defendants are accused of making false statements about the partnership with Novo, which was supposed to ensure access to Wegovy for Hims subscribers, and misrepresenting the offerings of compounded semaglutide products [3]. Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Class period is from June 22, 2023, to June 24, 2025, with a lead plaintiff deadline of August 25, 2025 [4]. - The complaint alleges that Sarepta misled investors about the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [4]. - Specific allegations include failure to disclose significant safety risks associated with ELEVIDYS, misleading statements about trial protocols, and the potential for regulatory scrutiny due to adverse events [4]. - Following a safety update on March 18, 2025, where a patient died after treatment, Sarepta's stock price fell by $27.81 per share, or 27.44% [5]. - Subsequent disclosures of additional patient deaths led to further declines in stock price, including a drop of $15.24 per share, or 42.12%, on June 15, 2025 [6].